Summit will examine issues facing sector.
EAST BRUNSWICK, N.J. -- Senior biopharmaceutical industry leaders from around the globe will convene here in October to discuss opportunities and challenges for reducing drug development costs and speeding products to market.
The Clinical Drug Development Summit, scheduled for October 23 to October 24, will focus on biopharmaceutical industry strategies and will feature three concurrent conferences and five industry-focused tracks. The conferences will be on strategic clinical outsourcing, clinical data management and Phase IV clinical trials.
Key issues to be explored include "offshoring," cost savings, contracting and partnerships, enhancing patient recruitment and retention, optimizing post-clinical research, effective use and adaptation of eClinical technologies, and integrating and implementation of EDC.
Participating companies include: Abbott Laboratories, Akros Pharma Inc., Amgen Inc., Astellas Pharma US, AstraZeneca PLC, Bayer Corp., Boehringer Ingelheim Ltd., Bristol-Myers Squibb Co., Centocor Inc., Daiichi Sankyo Inc., Eli Lilly and Co., Ferring Pharmaceuticals Inc., Genentech Inc., Genzyme Corp., Gilead Sciences Inc., GlaxoSmithKline PLC, Johnson & Johnson Pharmaceutical Research & Development LLC, King Pharmaceuticals, Merck & Co., NeoPharm Inc., Neurocrine Biosciences Inc., OrthoMcNeil Inc., Oscient Pharmaceuticals, OSI, Otsuka Pharmaceutical Co., Peninsula, Pfizer Inc., Procter & Gamble Co., Protein Design Labs Inc., Purdue Pharma LP, Roche, Schering-Plough Corp., Serono Inc., Takeda Pharmaceutical Co., Tengion Inc. and Threshold Pharmaceuticals Inc.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||ANNUAL REPORT OF RETAIL PHARMACY: BIOTECHNOLOGY, Clinical Drug Development Summit|
|Publication:||Chain Drug Review|
|Date:||Aug 28, 2006|
|Previous Article:||Era of personalized medicine nears.|
|Next Article:||BIO asserts FDA needs more funding to keep pace.|